<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/18/zacks-brokerages-anticipate-avenue-therapeutics-inc-nasdaqatxi-will-announce-earnings-of-0-29-per-share.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-18T11:54:35+00:00"/>
    <meta property="og:title" content="Zacks: Brokerages Anticipate Avenue Therapeutics Inc (NASDAQ:ATXI) Will Announce Earnings of -$0.29 Per Share"/>
    <meta property="og:description" content="Analysts expect Avenue Therapeutics Inc (NASDAQ:ATXI) to post ($0.29) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Avenue Therapeutics’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.29). Avenue Therapeutics posted earnings per share of ($0.38) during the same quarter last year, which would […]"/>
  </head>
  <body>
    <article>
      <h1>Zacks: Brokerages Anticipate Avenue Therapeutics Inc (NASDAQ:ATXI) Will Announce Earnings of -$0.29 Per Share</h1>
      <address><time datetime="2019-11-18T11:54:35+00:00">18 Nov 2019, 11:54</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/avenue-therapeutics-inc-logo.jpg"/>
      </figure>
      <p>Analysts expect Avenue Therapeutics Inc (NASDAQ:ATXI) to post ($0.29) earnings per share for the current fiscal quarter, <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks</a> reports. Zero analysts have issued estimates for Avenue Therapeutics’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.29). Avenue Therapeutics posted earnings per share of ($0.38) during the same quarter last year, which would indicate a positive year-over-year growth rate of 23.7%. The company is scheduled to announce its next earnings results on Tuesday, March 10th.</p>
      <p>According to Zacks, analysts expect that Avenue Therapeutics will report full-year earnings of ($1.66) per share for the current fiscal year, with EPS estimates ranging from ($1.78) to ($1.59). For the next financial year, analysts forecast that the firm will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.15) to ($0.77). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Avenue Therapeutics.</p>
      <p>Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.18.</p>
      <p>Separately, <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=ATXI">ValuEngine</a> upgraded shares of Avenue Therapeutics from a “sell” rating to a “hold” rating in a report on Friday.</p>
      <p>In other news, Director Elizabeth Garrett Ingram purchased 16,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were bought at an average price of $6.27 per share, with a total value of $100,320.00. Following the completion of the transaction, the director now directly owns 16,000 shares in the company, valued at approximately $100,320. The purchase was disclosed in a filing with the SEC, which is available through <a href="https://www.sec.gov/Archives/edgar/data/1644963/000114420419044714/xslF345X03/tv529486_form4.xml">this link</a>. Company insiders own 5.00% of the company’s stock.</p>
      <p>An institutional investor recently raised its position in Avenue Therapeutics stock. BlackRock Inc. boosted its holdings in shares of Avenue Therapeutics Inc (NASDAQ:ATXI) by 135.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,933 shares of the company’s stock after buying an additional 22,994 shares during the period. BlackRock Inc. owned about 0.24% of Avenue Therapeutics worth $251,000 as of its most recent SEC filing. 8.24% of the stock is owned by hedge funds and other institutional investors.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/ATXI/earnings/">ATXI</a> traded up $0.09 during mid-day trading on Monday, hitting $5.86. The company’s stock had a trading volume of 20,300 shares, compared to its average volume of 20,114. The firm has a 50-day moving average price of $5.64 and a 200 day moving average price of $5.72. The stock has a market capitalization of $96.14 million, a price-to-earnings ratio of -2.79 and a beta of -0.46. Avenue Therapeutics has a fifty-two week low of $4.13 and a fifty-two week high of $7.98.</p>
      <p>
        <b>Avenue Therapeutics Company Profile</b>
      </p>
      <p>Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.</p>
      <p>Recommended Story: <a href="https://www.marketbeat.com/financial-terms/what-is-an-inverted-yield-curve/">Inverted Yield Curve</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=ATXI">Get a free copy of the Zacks research report on Avenue Therapeutics (ATXI)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ATXI"/>
      </figure>
    </article>
  </body>
</html>